Shopping Cart
- Remove All
- Your shopping cart is currently empty
Etaracizumab (LM 609) is a humanized monoclonal antibody targeting integrin αvβ3, inhibiting angiogenesis and melanoma growth, used in the study of melanoma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $289 | In Stock | |
5 mg | $753 | In Stock | |
10 mg | $1,180 | In Stock | |
25 mg | $1,780 | In Stock | |
50 mg | $2,380 | In Stock |
Description | Etaracizumab (LM 609) is a humanized monoclonal antibody targeting integrin αvβ3, inhibiting angiogenesis and melanoma growth, used in the study of melanoma. |
In vivo | In the SKOV3ip1 model, both Bevacizumab (5 mg/kg twice weekly) and Etaracizumab (10 mg/kg twice weekly) reduced tumor growth by 52-63%, compared with either drug alone. The combination treatment reduced growth by 63-74%. |
Alias | MEDI523, MEDI 523, LM609, LM 609, Anti-αvβ3 Integrin Recombinant Antibody |
Molecular Weight | 144.3 (kDa) |
Cas No. | 892553-42-3 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.